Research Experience

For the past 25 years, Dr. Fisher has been involved in clinical research trials as a Primary Investigator. He has participated in phase 2, 3 and 4 clinical trials for osteoporosis, analgesics, NSAIDS COX 2s for osteoarthritis and rheumatoid arthritis, GI tolerability, pain management, low back pain, and IV biologics for rheumatoid arthritis.

Fisher Clinical Research has a dedicated staff to assist with the patients' needs. The office is conveniently located in Haddon Heights, New Jersey, where it is easily accessible by I-295 and the White Horse Pike (Route 30).

All patients are treated with the highest level of courtesy and accommodation. Referrals from physicians are appreciated and treated with confidentiality. No patients seen on referral for our clinical trials will be seen in the office for rheumatic care outside of the clinical trial unless the referring physician personally calls and requests it. This is the policy of the Center in order to avoid all conflicts of interest and the relationship of the referring physicians and their patients.

Asthma

Sponsor: Skye Pharma

Phase: III

Protocol: SKY2028-3-001

Year: 2005

 

A randomized, Double Blind, Placebo-Controlled, Parallel Group, Stratified, Multi-center, 12 week study comparing the safety and efficacy of Fluticasone and Formoterol Combination

(Fluti Form TM 100/10 ug twice daily) in a single inhaler (sky pharma HFA pMDI) with the administration of Placebo or Fluticasone 100 ug twice daily alone in adolescent and adult patients with mild to moderate asthma.

Chronic Low Back Pain

Sponsor: DOV

Phase: III

Protocol: DOV-075-020-US

Year: 2004

 

Double blind, placebo-controlled randomized study of Bicifadine in the treatment of Chronic Low Back Pain.

Sponsor: Johnson & Johnson

Phase: III

Protocol: R331333-PAI-3004

Year: 2006

 

A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.

Sponsor: Johnson & Johnson

Phase: III

Protocol: R331333-PAI-3011

Year: 2007

 

A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm with controlled Adjustments of Dose to Evaluate the Efficacy and Safety of CG5503 Extended Release (ER) in subjects with Moderate to Severe Chronic Low Back Pain.

Sponsor: Johnson & Johnson

Phase: III

Protocol: R331333-PAI-3010

Year: 2007

 

Open-Label Extension, Single Arm, Flexible-Dosing with CG5503 Extended-Release (ER) in subjects with moderate to Severe Chronic Pain.

COPD

Sponsor: Altana Pharma

Phase: III

Protocol: BY217-M2-124

Year: 2006

 

Effect of Roflumilast, on exacerbation rate in patients with COPD. A 52 week, Double-Blind Study with 500 mcg Roflumilast once daily versus placebo.

Fibromyalgia

Sponsor: Forest Research Institute

Phase: III

Protocol: MLN-MD-03

Year: 2006

 

A pivotal, multi center, double blind, randomized, placebo controlled monotherapy study of Milnacipran for the treatment of fibromyalgia.

Sponsor: Forest Research Institute

Phase: III

Protocol: MLN-MD-06

Year: 2006

 

A Multicenter, Open-Label, Flexible Dosing Study of Milnacipran for the treatment of Fibromyalgia.

Insomnia
Triazolam and Temazepam
Insomnia treatment study, comparing Triazolam and Temazepam.

Lupus

Sponsor: MedImmune

Phase: IIA

Protocol: MI-CP179

Year: 2008

 

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the safety and tolerability of multiple subcutaneous doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in subjects with Systemic Lupus Erythematosus.

Opioid-Induced Bowel Dysfunction

Mucosa Trial
Double blind study evaluating Cytotec plus NSAID and the risk of GI complications.

Sponsor: Glaxo Smith Kline

Phase: II B

Protocol: SB-767905/011

Year: 2003

 

Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain.

Sponsor: Glaxo Smith Kline

Phase: III

Protocol: SB/767905-012/014

Year: 2003

 

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Alvimopan for 12 Weeks and 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.

Sponsor: Glaxo Smith Kline

Phase:

Protocol: ABD104225

Year: 2004

 

Prospective, Observational Study, to Characterize GI Function and Morbidity, and the Humanistic Burden of Illness Among Opioid-Naive Subjects with Pain Treated with Opioid Therapy.

Sponsor: Wyeth

Phase: III

Protocol: 3200A3-200-WW

Year: 2006

 

A Multicenter, Randomized, Double-Blind, Parallel-Group, study of Oral MOA-728 for the treatment of Opioid-Induced Bowel Dysfunction in subjects with Chronic Non-Malignant Pain.

Osteoarthritis

Sponsor: Novartis

Phase: III

Study: Voltar

 

 

Twelve patients were enrolled for a clinical trial of Voltaren, a new NSAID.

Sponsor: Glaxo Smith Kline

Study: Nabumetone

Phase: III

 

 

Study comparing a new NSAID, Nabumetone, to another NSAID in a clinical trial.

Sponsor: Merck

Phase: IIb/III

Study: Rofecoxib

 

 

Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with osteoarthritis.

Sponsor: Merck

Phase: III

Protocol: 066-01

Year: 2002

 

A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.

Sponsor: Merck

Phase: III

Protocol: 071-01

Year: 2003

 

A 12 week, Randomized, Placebo and Active Comparator Controlled, Parallel Group, Double Blind Study to assess the safety and efficacy of Etoricoxib 30 mg verse Ibuprofen 2400 mg in patients with osteoarthritis.

Sponsor: Pain Therapeutics Inc.

Phase: III

Protocol: PTI-801-XH

Year: 2003

 

A Multi-center, Randomized, Double-Blind, Active- and Placebo-Controlled, Efficacy and Safety Study of Oxycodone HCI and Low Dose Naltrexone HCI in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee.

Sponsor: Merck

Phase: III

Protocol: 077-00/COX553

Year: 2004

 

26 Week Randomized, Placebo-and Active-Comparator-Controlled, Parallel-Group, Double-Blind, Two Part study to assess the Safety and Efficacy of Etoricoxib vs. Celecoxib in Patients with Osteoarthritis.

Sponsor: Purdue Pharma

Phase: IV

Protocol: OXY4003

Year: 2004

 

Multicenter Usual Care Open-Labeled Randomized-Parallel-Group Trial Comparing the Impact of Therapy with Oxycontin vs. Usual Care in Moderate to Severe Osteoarthritis of the Hip or Knee.

Sponsor: Novartis

Phase: III

Protocol: VOSG-PN-310

Year: 2004

 

A 12 Week, Randomized, Double-Blind, Multicenter, Vehicle-Controlled, Parallel Group to Assess the Efficacy and Safety of the Diclofenic Sodium Gel 1% for the Relief of Signs and Symptoms in Patients with Osteoarthritis of the Knee.

Sponsor: Labopharm

Phase: III

Protocol: MDT3-005

Year: 2004

 

A Two-Arm study Comparing the Analgesic Efficacy and Safety of Tramadol HCI Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the knee.

Sponsor: Merck

Phase: III

Protocol: MK-072-00

Year: 2005

 

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: MK-0663-066

Phase: III

Protocol: MK-0663-066

Year: 2005

 

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: Johnson & Johnson

Phase: III

Protocol: R331333-PAI-3004

Year: 2006

 

A Randomized, Double-Blind, Active-Controlled, Parallel Group, 90 Day safety study of CG5503 Immediate Release or Oxycodone Immediate Release, in subjects with chronic pain from Low Back Pain or Osteoarthritis of the Hip or Knee.

Sponsor: Riant

Phase: II

Protocol: RN624-CL006

Year: 2006

 

A Randomized, Parallel-Arm, Placebo-Controlled, Double-Blind, Multiple Dose Study of the safety and efficacy of RN624 in adults with moderate to severe pain due to Osteoarthritis of the knee.

Sponsor: Biovail

Phase: III

Protocol: TMX-301

Year: 2006

 

A Open-Label, Long Term Safety Study of Tramadol Hydrochloride Extended Release and Meloxicam QD Combination in the Treatment of Moderate to Moderately Severe Pain Associated with Osteoarthritis.

Sponsor: Pfizer

Phase: IV

Protocol: A3191172

Year: 2006

 

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.

Sponsor: CombinatoRx

Phase: II

Protocol: CRX-102-006

Year: 2007

 

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to evaluate the efficacy of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.

Sponsor: CombinatoRx

Phase: II

Protocol: CRX-102-006E

Year: 2007

 

A Randomized, Double-Blind, Multi-Center, 1 year extension study to evaluate the long-term safety, tolerability and effectiveness of CRX-102 in subjects with Symptomatic Knee Osteoarthritis.

Osteoporosis

Sponsor: Merck

Phase: IV

Protocol: MK-217

Year: 2000

 

A Multicenter, Open Label, Randomized, Crossover, Preference Study of oral Alendronate Sodium 70 mg once weekly and 10 mg once daily in postmenopausal women with osteoporosis.

Sponsor: Eli Lilly & Company

 

Protocol: B3D-US-GHCQ:

Year: 2005

 

Direct assessment of non vertebral fractures in community experience (DANCE).

Rheumatoid Arthritis

Sponsor: Ortho-McNeil, Inc.

Study: Ultram

 

A double blind, randomized, parallel group, multicenter comparison of the efficacy and safety of Mycophenolate mofetil p.o. (Xg b.i.d.) and placebo in patients with active rheumatoid arthritis (six month efficacy study) who are candidates for immunosuppressive therapy for rheumatoid arthritis.

Sponsor: Roche

Study: Meloxicam

 

A multicenter, double blind, double dummy, randomized, parallel group trial to compare the efficacy and safety of three doses of Meloxicam with Naproxen and placebo on patients with rheumatoid arthritis.

Sponsor: Merck

Study: Rofecoxib

 

Randomized double blind multicenter study evaluating the tolerability and effectiveness of Rofecoxib versus Naproxen in patients with rheumatoid arthritis.

Sponsor: Wyeth

Protocol: RADIUS 1

Year: 2002

 

Rheumatoid Arthritis DMARD Intervention and Utilization Study.

Sponsor: Merck

Phase: III

Protocol: 066-01

Year: 2002

 

A Randomized Double Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis and Rheumatoid Arthritis.

Sponsor: Wyeth

 

Protocol: RADIUS 2

Year: 2003

 

Rheumatoid Arthritis DMARD Intervention and Utilization Study.

Sponsor: Merck

Phase: III

Protocol: MK-0663

Year: 2003

 

A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib vs. Diclofenac Sodium in Patients with Rheumatoid Arthritis.

Sponsor: Hoffmann La Roche

Phase: III

Protocol: WA18063

Year: 2005

A randomized, double blind placebo controlled parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.

Sponsor: Arakis

Phase: II

Protocol: P-AD452-022

Year: 2005

 

A randomized, double-blind, multicenter, placebo controlled, dose ranging parallel group study to compare the efficacy, safety and tolerability of three strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking Methotrexate.

Sponsor: Hoffmann La Roche

Phase: III

Protocol: WA18696

Year: 2005

 

Long term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA Core Studies.

Sponsor: Merck

Phase: III

Protocol: MK-072-00

Year: 2005

 

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Extoricoxib in patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: MK-0663-066

Phase: III

Protocol: MK-0663-066

Year: 2005

 

A Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib patients with Osteoarthritis or Rheumatoid Arthritis.

Sponsor: Genentech

Phase: III

Protocol: U3384g

Year: 2006

 

A randomized, double blind, placebo controlled, multi center study of re-treatment with Rituximab in subjects with rheumatoid arthritis receiving background methotrexate.

Sponsor: Hoffmann La Roche

Phase: III

Protocol: WA17824

Year: 2006

 

A randomized, double blind, double dummy, parallel group study of the safety and efficacy of MRA monotherapy vs. methotrexate monotherapy, in patients with active rheumatoid arthritis.

Sponsor: Pfizer

Phase: IV

Protocol: A3191172

Year: 2006

 

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients with or at high risk for cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.

Sponsor: Genentech

Phase: III

Protocol: U3924g

Year: 2007

 

An Open-Label, Prospective Study of the safety of Rituximab in combination with other disease-modifying Anti-Rheumatic Drugs in subjects with Active Rheumatoid Arthritis.

Sponsor: Genentech

Phase: III

Protocol: WA20494/ACT3985g

Year: 2007

 

A Program investigating two dose regimens of Rituximab, two infusions of either 500 mg or 1000 mg separated by 14 days between treatments is underway in patients with Rheumatoid Arthritis unresponsive to Methotrexate and in patients with Rheumatoid Arthritis but naive to Methotrexate Treatment.

Sponsor: Genentech

Phase: III

Protocol: WA20495/ACT3986g

Year: 2007

 

A Randomized, Double-Blind, Parallel Group, International Study to evaluate the safety and efficacy of Ocrelizumab, compared to Placebo in patients with Active-Rheumatoid Arthritis who have inadequate response to at least one Anti-TNF a Therapy.

Sponsor: Pfizer

Phase: II

Protocol: A7701005

Year: 2007

 

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of CP-195543 and Celecoxib Dual Therapy in the treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are inadequately controlled on Methotrexate.

Sponsor: CombinatoRx

Phase: II B

Protocol: CRX-102-007

Year: 2007

 

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRX-102 over each of its components when given to subject with active Rheumatoid Arthritis.

Camden County, NJ Rheumatologist
Mark Fisher, MD
713 Station Ave
Haddon Heights, NJ 08035
(856) 547-8004